ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Study: Reducing Cardiovascular Risks Helps Lupus Patients

Deborah Levenson  |  Issue: October 2025  |  

Because cardiovascular disease in lupus is driven by the cumulative, long-term burden of both traditional and disease-specific factors, rheumatologists “should prioritize sustained disease remission, strict control of traditional CVD risk factors, consistent lifestyle modifications, early identification of persistent antiphospholipid antibody positivity, long-term hydroxychloroquine use and reduced glucocorticoid exposure,” Dr. Tektonidou suggests.

Deborah Levenson is a writer and editor based in College Park, Md.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Papazoglou N, Sfikakis PP, Tektonidou MG. Atherosclerotic plaque progression and incident cardiovascular events in a 10-year prospective study of patients with systemic lupus erythematosus: The impact of persistent cardiovascular risk factor target attainment and sustained DORIS remission. Arthritis Rheumatol. 2025 Jun;77(6):716–726.

Related Articles

    A Heart In Danger

    Rheumatologists should monitor and aggressively treat cardiac risk factors in patients with lupus and rheumatoid arthritis

    Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

    WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

    Top Research in Rheumatoid Arthritis Presented at ACR Convergence 2024

    Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…

    Biologics May Prevent Cardiovascular Events in RA Patients

    RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.